论文部分内容阅读
为确定能否根据第6天的骨髓情况调整AML患者的诱导缓解方案以提高CR率,且不增加因毒性死亡的人数,本文对252例初治AML患者(<60岁)进行了研究。治疗用DA或AA方案(DNR 45mg/m~2×3天或ADM30mg/m~2×3天,Ara-C 100mg/m~2×7或10天)。于化疗第6天进行骨髓活检和骨穿,凡骨髓活检细胞而积>30%或骨穿发现异常细胞>10%的患者归入扩大的诱导化疗组(即于第8、9、10三天给予Ara-C3g/m~2、V Dq12小时,共6次),不到此标准者则归人不扩大诱导化疗组。两组治疗前条件基本相同,只不过扩大组的SGOT稍低,血清白蛋白稍高,以及男性患者的比例稍高。与此同时,另
To determine if an induction remission program can be adjusted for AML patients based on bone marrow conditions on day 6 to improve CR rates without increasing the number of deaths due to toxicity, 252 naïve AML patients (<60 years) were studied. Treatment with DA or AA regimen (DNR 45 mg / m to 2 x 3 days or ADM 30 mg / m to 2 x 3 days, Ara-C 100 mg / m to 2 x 7 or 10 days). Patients who underwent bone marrow biopsy and osteoporosis on day 6 of chemotherapy with> 30% of bone marrow biopsy cells or> 10% of abnormal bone cells found bone involvement were assigned to an expanded induction chemotherapy group (ie, days 8, 9, and 10 Given Ara-C3g / m ~ 2, V Dq12 hours, a total of 6 times), less than this standard is not to expand the induction chemotherapy group. The pretreatment conditions were similar between the two groups except that in the enlarged group the SGOT was slightly lower, serum albumin was slightly higher, and the proportion of male patients was slightly higher. At the same time, the other